Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
13(59%)
Results Posted
100%(1 trials)

Phase Distribution

Ph phase_1
8
36%
Ph phase_2
11
50%
Ph phase_3
3
14%

Phase Distribution

8

Early Stage

11

Mid Stage

3

Late Stage

Phase Distribution22 total trials
Phase 1Safety & dosage
8(36.4%)
Phase 2Efficacy & side effects
11(50.0%)
Phase 3Large-scale testing
3(13.6%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

13

trials recruiting

Total Trials

22

all time

Status Distribution
Active(21)
Completed(1)

Detailed Status

Recruiting13
Not yet recruiting8
Completed1

Development Timeline

Analytics

Development Status

Total Trials
22
Active
13
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 18 (36.4%)
Phase 211 (50.0%)
Phase 33 (13.6%)

Trials by Status

completed15%
not_yet_recruiting836%
recruiting1359%

Recent Activity

Clinical Trials (22)

Showing 20 of 22 trialsScroll for more
NCT07525466Phase 1

Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH)

Recruiting
NCT07300514Phase 3

Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell Lymphoma

Recruiting
NCT07380984Phase 2

PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCL

Recruiting
NCT07414758Phase 3

Golidocitinib Versus Placebo as Maintenance Therapy in PTCL Patients With Response (CR/PR) After First-Line Chemotherapy

Recruiting
NCT06630091Phase 2

A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study

Recruiting
NCT07369739Phase 2

Golidocitinib Combined With Selinexor for CAEBVD

Recruiting
NCT07339345Phase 2

Prospective Single-Arm Clinical Trial of GO Regimen for HLH.

Recruiting
NCT07339527Phase 1

EZH2 Inhibitor Zeprumetostat in Combination Therapy for Patients With Relapsed or Refractory Mature T-cell and NK-cell Lymphomas

Not Yet Recruiting
NCT07093710Phase 1

Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma

Recruiting
NCT07303881Phase 2

Golidocitinib for Refractory Immune-related Hematologic Toxicities of Advanced Lung Cancer

Not Yet Recruiting
NCT07279584Phase 2

Golidocitinib Combined With GemOx in RR PTCL

Not Yet Recruiting
NCT07234162Phase 3

A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)

Recruiting
NCT07209163Phase 1

Combination Therapy With Tazemetostat in Relapsed and Refractory Peripheral T-cell Lymphoma

Not Yet Recruiting
NCT07196163Phase 1

An Exploratory Study of Golidocitinib in Adult Patients With ITP

Not Yet Recruiting
NCT07032532Phase 2

Assessing An Oral JAK1 Inhibitor, Golidocitinib, in Patients Who Have Newly Diagnosed Peripheral T-Cell Lymphoma (JACKPOT23)

Not Yet Recruiting
NCT06969612Phase 1

A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLC

Recruiting
NCT06966154Phase 1

A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL

Recruiting
NCT04105010Phase 1

Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8)

Completed
NCT06733051Phase 2

Phase II Study of Golidocitinib and Benmelstobart in Patients with R/R ENKTL (JACKPOT50)

Recruiting
NCT06701344Phase 2

Go-CHOP in de Novo Intestinal T-cell Lymphoma Patients

Not Yet Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
22